MOLECULAR TEMPLATES INC. news, videos and press releases
For more news please use our advanced search feature.
MOLECULAR TEMPLATES INC. - More news...
MOLECULAR TEMPLATES INC. - More news...
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
- Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
- Molecular Templates, Inc. Provides Interim Update
- Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
- Molecular Templates, Inc. Provides Interim Update
- Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
- Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
- Molecular Templates to Participate in Upcoming Investor Conferences
- Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
- Molecular Templates Announces 1-for-15 Reverse Stock Split
- Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
- Molecular Templates Announces Executive Leadership Changes
- Molecular Templates Announces Up to $40 Million Private Placement Offering
- Molecular Templates Announces Debt Payoff and Restructuring
- Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
- Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
- Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
- Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
- Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
- Molecular Templates Announces Participation in Upcoming Conferences
- Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
- Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
- Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
- Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
